---
title: 'æŠ—è¡°è€æ˜æ˜Ÿ NMN çœŸçš„èƒ½é”åˆ°æŠ—è¡°è€çš„ç›®çš„å—ï¼Ÿ'
description: 'æ ¹æ“šè¥¿å…ƒ 2020 å¹´ä¸‰æœˆä»½å°ç£äººå£çµ±è¨ˆè³‡æ–™é¡¯ç¤ºï¼Œå°ç£è€å¹´äººå£ä½”ç¸½äººå£ 15% ä»¥ä¸Šï¼Œæ­£å¼å®£å‘Šå°ç£é€²å…¥äººå£è² æˆé•·ï¼Œæœªä¾†å°‡å¿«é€Ÿæˆé•·åˆ° 40 % ä»¥ä¸Šã€‚è€ŒæŠ—è¡°è€çš„è—¥ç‰©ç ”ç™¼ä¸€ç›´éƒ½æ˜¯äººé¡åŠªåŠ›é‘½ç ”çš„é†«å­¸èª²é¡Œã€‚è¸é†¯èƒºå–®æ ¸è‹·é…¸ï¼ˆ Nicotinamide Mononucleotideï¼ŒNMN ï¼‰ç„¡ç–‘æ˜¯è¿‘å¹¾å¹´ä¾†æœ€è¢«é—œæ³¨çš„é …ç›®ä¹‹ä¸€ï¼Œå› ç‚ºæœ‰è¨±å¤šå¤§é‡çš„ç§‘å­¸è­‰æ“šæ­£åœ¨å‘ˆç¾ï¼Œå¸‚å ´ä¸Šç³ç‘¯æ»¿ç›®éƒ½åœ¨éŠ·å”® NMN ç›¸é—œçš„ç”¢å“ï¼Œç”šè‡³è¢«æ¨ä¸ŠæŠ—è¡°è€ç•Œä¸­ã€Œä¸è€è—¥ã€å¯¶åº§ã€‚å…ˆèªªçµè«–ï¼Œå¾å„åœ‹çš„è‡¨åºŠå¯¦é©—é¡¯ç¤ºé€éè£œå…… NMN ä¾†è®“ã€Œéª¨éª¼è‚Œçš„ç¶­æŒèˆ‡æŠ—è¡°è€ã€æ˜¯æœ‰æ•ˆçš„ï¼Œä½†æ˜¯å…¨èº«æ€§çš„æŠ—è¡°è€é‚„åšä¸åˆ°ã€‚å¦å¤–ï¼Œå¸‚é¢ä¸Šæœ‰è¨±å¤šè™Ÿç¨± NAD+ çš„è£œå……å“ï¼Œ NAD+ çš„å‰é©…ç‰©æœ‰å¾ˆå¤šç¨®é¡å¦‚ NR ã€ NAM ã€ NMN éƒ½æ˜¯ï¼Œä½†æ˜¯ç›®å‰è‡¨åºŠå¯¦é©—åšæœ€å¤šçš„æ˜¯ NR èˆ‡ NMN ã€‚è€Œæ ¹æ“šå ±å°ï¼Œåœ¨ç¾åœ‹é›»å•†äºé¦¬éœå¹³å°ï¼ˆAmazonï¼‰ä¸Šæ‰€è²©å”® 22 éš»æœ‰é—œ NMN çš„è³£æœ€å¥½çš„ç”¢å“ä¸­ï¼Œç«Ÿç„¶æœ‰ 64ï¼… ç”¢å“å¹¾ä¹ä¸å« NMN ï¼ï¼ˆåƒå¿ƒé…¸çš„ï¼‰è¦å…¨é¢äº†è§£ NMN ï¼Œå°±å¾—å…ˆäº†è§£ä»–çš„è¡ç”Ÿç‰©â€”è¸é¹¼é†¯è…ºå˜Œå‘¤äºŒæ ¸è‹·é…¸ï¼ˆNicotinamide Adenine Dinucleotideï¼ŒNAD ï¼‰æ‰è¡Œï¼Œå› ç‚º NMN æ˜¯ NAD çš„å…ˆé£éƒ¨éšŠï¼Œä¸‹é¢å¯ä»¥è½æˆ‘åˆ†æã€‚'
pubDate: 2024-12-08T13:26:25+08:00
---

_3.1K_

å…§å®¹ç›®éŒ„

Toggle

  * å‰è¨€
  * ä»€éº¼æ˜¯ NADï¼Ÿ
  * NAD+ èˆ‡è€åŒ–é—œä¿‚
  * ä¸‹é™çš„åŸå› ï¼Ÿ
  * å¹´ç´€å¢é•·è®“ NAD+ æ¶ˆè€—å¢åŠ 
  * æé«˜ç”Ÿç‰©é«”å…§ NADï¼‹ çš„æ–¹æ³•ï¼š
    * ç¬¬ä¸€ç¨®ã€æå‡ NAD+ æ´»æ€§
    * ç¬¬äºŒç¨®ã€è£œå…… NAD+ å‰é©…ç‰©
      * è£œå……è¸é¹¼é†¯èƒºå–®æ ¸è‹·é…¸ï¼ˆNicotinamide Mononucleotideï¼ŒNMNï¼‰
      * è£œå……è¸é¹¼é†¯èƒºæ ¸ç³–ï¼ˆNicotinamide Riboseï¼ŒNRï¼‰
      * è£œå……è¸é¹¼é†¯èƒºï¼ˆNicotinamideï¼ŒNAMï¼‰
    * ç¬¬ä¸‰ç¨®ã€æ¸›å°‘ NAD+ æ¶ˆè€—
    * ç¬¬å››ç¨®ã€å¢åŠ  NAD+ åˆæˆèƒ½åŠ›
  * ç¾åœ‹è‡¨åºŠç ”ç©¶
  * æ—¥æœ¬è‡¨åºŠç ”ç©¶
  * ä¸­åœ‹è‡¨åºŠç ”ç©¶
  * å¤¢ç¢
  * æ³¨æ„ï¼ä½ è²·åˆ°çš„çœŸçš„æ˜¯ NMN å—ï¼Ÿ
  * æ‰“ç ´å±€é¢çš„è®Šæ•¸
  * ä»¥å¾Œé‚„èƒ½è²·åˆ° NMN å—ï¼Ÿ
  * ç†±é‡é™åˆ¶æ¨¡æ“¬ç‰©æ˜¯è§£æ–¹

## **å‰è¨€**

æ ¹æ“šè¥¿å…ƒ 2020 å¹´ä¸‰æœˆä»½å°ç£äººå£çµ±è¨ˆè³‡æ–™é¡¯ç¤ºï¼Œå°ç£è€å¹´äººå£ä½”ç¸½äººå£ 15% ä»¥ä¸Šï¼Œæ­£å¼å®£å‘Šå°ç£é€²å…¥äººå£è² æˆé•·ï¼Œæœªä¾†å°‡å¿«é€Ÿæˆé•·åˆ° 40 % ä»¥ä¸Šã€‚

è€ŒæŠ—è¡°è€çš„è—¥ç‰©ç ”ç™¼ä¸€ç›´éƒ½æ˜¯äººé¡åŠªåŠ›é‘½ç ”çš„é†«å­¸èª²é¡Œã€‚

äººå£è€åŒ–

**è¸é†¯èƒºå–®æ ¸è‹·é…¸** ï¼ˆ Nicotinamide Mononucleotideï¼ŒNMN ï¼‰ç„¡ç–‘æ˜¯è¿‘å¹¾å¹´ä¾†æœ€è¢«é—œæ³¨çš„é …ç›®ä¹‹ä¸€ï¼Œå› ç‚ºæœ‰è¨±å¤šå¤§é‡çš„ç§‘å­¸è­‰æ“šæ­£åœ¨å‘ˆç¾ï¼Œå¸‚å ´ä¸Šç³ç‘¯æ»¿ç›®éƒ½åœ¨éŠ·å”® NMN ç›¸é—œçš„ç”¢å“ï¼Œç”šè‡³è¢«æ¨ä¸ŠæŠ—è¡°è€ç•Œä¸­ã€Œä¸è€è—¥ã€å¯¶åº§ã€‚

å…ˆèªªçµè«–ï¼Œå¾å„åœ‹çš„è‡¨åºŠå¯¦é©—é¡¯ç¤ºé€éè£œå…… NMN ä¾†è®“ã€Œ**éª¨éª¼è‚Œçš„ç¶­æŒèˆ‡æŠ—è¡°è€** ã€æ˜¯æœ‰æ•ˆçš„ï¼Œä½†æ˜¯ã€Œ**å…¨èº«æ€§** ã€çš„æŠ—è¡°è€é‚„åšä¸åˆ°ã€‚

**è£œå…… NMN ä¸èƒ½ç›´æ¥å¢é•·å£½å‘½**

ä½†æ˜¯å°æ–¼éª¨éª¼è‚Œçš„ç¶­æŒå¾ˆæœ‰ç”¨ï¼Œé€™ä¹Ÿæ˜¯ç¾ä»£äººè‚Œå°‘ç—‡è »éœ€è¦çš„è£œå……ã€‚

é™¤äº†é€éä½œé˜»åŠ›è¨“ç·´+è›‹ç™½è³ªçš„è£œå……å¤–ï¼Œå¯ä»¥ç›´æ¥å¾—åˆ°å¥½è™•çš„åœ°æ–¹ã€‚

å¦å¤–ï¼Œå¸‚é¢ä¸Šæœ‰è¨±å¤šè™Ÿç¨± NAD+ çš„è£œå……å“ï¼Œ NAD+ çš„å‰é©…ç‰©æœ‰å¾ˆå¤šç¨®é¡å¦‚ NR ã€ NAM ã€ NMN éƒ½æ˜¯ï¼Œä½†æ˜¯ç›®å‰è‡¨åºŠå¯¦é©—åšæœ€å¤šçš„æ˜¯ NR èˆ‡ NMN ã€‚

è€Œæ ¹æ“šå ±å°ï¼Œåœ¨ç¾åœ‹é›»å•†äºé¦¬éœå¹³å°ï¼ˆAmazonï¼‰ä¸Šæ‰€è²©å”® 22 éš»æœ‰é—œ NMN çš„è³£æœ€å¥½çš„ç”¢å“ä¸­ï¼Œç«Ÿç„¶æœ‰ 64ï¼… ç”¢å“å¹¾ä¹ä¸å« NMN ï¼ï¼ˆåƒå¿ƒé…¸çš„ï¼‰

è€Œè¦å…¨é¢äº†è§£ NMN ï¼Œå°±å¾—å…ˆäº†è§£ä»–çš„è¡ç”Ÿç‰©**â€”è¸é¹¼é†¯è…ºå˜Œå‘¤äºŒæ ¸è‹·é…¸** ï¼ˆNicotinamide Adenine Dinucleotideï¼ŒNAD ï¼‰æ‰è¡Œï¼Œå› ç‚º NMN æ˜¯ NAD+ çš„å…ˆé£éƒ¨éšŠï¼Œä¸‹é¢å¯ä»¥è½æˆ‘åˆ†æã€‚

nmnèˆ‡nadç²’ç·šé«”é—œä¿‚

è‘—åçš„æŠ—è¡°è€ç§‘å­¸å®¶**å¤§è¡›ï¼å®‰å¾·é­¯ï¼è¾›å…‹èŠ** ï¼ˆDavid Andrew Sinclairï¼‰æ•™æˆèªç‚º NAD+ æ˜¯ç¹¼**ç™½è—œè˜†é†‡** ï¼ˆResveratrolï¼‰å¾Œæœ€å…·æœ‰å»¶é•·ç”Ÿå‘½æ•ˆæœçš„ç‰©è³ªå€™é¸ä¹‹ä¸€ã€‚

## **ä»€éº¼æ˜¯ NADï¼Ÿ**

NAD+ é›–ç„¶å¾è¢«ç™¼ç¾è‡³ä»Šå·²ç¶“ç¶“éç™¾å¹´ä»¥ä¸Šï¼Œä¸éå› ç‚ºæŠ—è¡°è€çš„è­°é¡Œè€Œæˆç‚ºç›®å‰ç”ŸåŒ–é†«å­¸ç ”ç©¶çš„ä¸€å¤§ç„¦é»ã€‚

NAD å…¨åç‚º**è¸é¹¼é†¯èƒºè…ºå˜Œå‘¤äºŒæ ¸è‹·é…¸** ï¼ˆNicotinamide Adenine Dinucleotideï¼ŒNADï¼‰ï¼Œå®ƒå»£æ³›åƒèˆ‡ç”Ÿç‰©é«”å…§çš„ç”Ÿç†æ´»å‹•ï¼Œæ˜¯èº«é«”ä¸­æ°§åŒ–é‚„åŸåæ‡‰ä¸­é‡è¦çš„**è¼”é…¶** ï¼ˆCoenzymeï¼‰ã€‚

å¦‚**ä¸‰ç¾§é…¸å¾ªç’°** ï¼ˆTricarboxylic Acid cycleï¼ŒTCA cycleï¼‰ã€**è„‚è‚ª Î² æ°§åŒ–ä½œç”¨** ï¼ˆÎ²-oxidationï¼‰ç­‰ï¼Œåœ¨é†£é¡ã€è„‚è‚ªã€æ°¨åŸºé…¸ç­‰ç‡Ÿé¤Šç‰©è³ªçš„ä»£è¬åˆ©ç”¨éç¨‹ä¸­å…·æœ‰é‡è¦æ„ç¾©ã€‚

ç ”ç©¶é¡¯ç¤º NAD+ ç¼ºä¹èˆ‡åŒ…æ‹¬ä»£è¬ç–¾ç—…ã€ç™Œç—‡ã€ç¥ç¶“é€€åŒ–æ€§ç–¾ç—…ã€é˜¿èŒ²æµ·é»˜ç—‡èˆ‡è¡°è€æœ‰é—œã€‚

NAD æ–¼è¥¿å…ƒ 1906 å¹´é¦–æ¬¡è¢«è‹±åœ‹ç”ŸåŒ–å­¸å®¶**é˜¿ç‘Ÿï¼å“ˆç™»** ï¼ˆArthur Hardenï¼‰èˆ‡**å¨å»‰ï¼ç´„ç¿°ï¼æ¥Š** ï¼ˆWilliam John Youngï¼‰æ‰€ç™¼ç¾ï¼Œç•¶æ™‚å…©äººåˆ©ç”¨é…µæ¯ä»£è¬ç³–ä¸¦ç”¢ç”Ÿé…’ç²¾å’ŒäºŒæ°§åŒ–ç¢³ã€‚

ä»–åˆ©ç”¨é€æçš„æ–¹æ³•ï¼ˆä»–å°‡é…µæ¯èƒå–æ¶²æ”¾å…¥ä¸€å€‹è¢‹ä¸­ï¼Œå†å°‡è¢‹å­æ”¾å…¥ç´”æ°´ä¸­ï¼Œè®“è¢‹ä¸­çš„å°åˆ†å­ç‰©è³ªé€šéè¢‹å­ï¼Œè€Œå¤§åˆ†å­ç‰©è³ªå‰‡ç•™åœ¨è¢‹ä¸­ï¼‰å°‡é…µæ¯èƒå–æ¶²åˆ†æˆå…©å€‹éƒ¨åˆ†ã€‚

å“ˆç™»æ•™æˆç™¼ç¾åœ¨è¢‹ä¸­çš„å¤§åˆ†å­ç‰©è³ªä¸¦ä¸èƒ½ç”¢ç”Ÿç™¼é…µä½œç”¨ï¼Œä½†å°‡é€æéçš„æ°´å†åŠ å›è¢‹ä¸­å°±å¯ä»¥ç™¼ç”Ÿé†±é…µä½œç”¨äº†ï¼Œé€™èªªæ˜äº†é…µç´ å¯ä»¥åˆ†æˆå…©å€‹éƒ¨åˆ†ã€‚

ä»–ç™¼ç¾äº†é…µç´ ä½œç”¨æ™‚éœ€è¼”é…¶çš„å¹«å¿™ï¼Œä¸”ä¹‹å¾Œçš„å¯¦é©—ç™¼ç¾æ­¤ç‰©è³ªåœ¨æ°´ä¸­ä¸¦ä¸æœƒå› ç†±è€Œå—åˆ°ç ´å£ã€‚

é€™å€‹ç‰©è³ªå°±æ˜¯ NAD ã€‚

å¾Œä¾†**æ¼¢æ–¯ï¼å¡çˆ¾ï¼å¥§å¤æ–¯ç‰¹ï¼è¥¿è’™ï¼é¦®ï¼å¥§ä¼Šå‹’-åˆ‡çˆ¾å¹³** ï¼ˆHans Karl August Simon von Euler-Chelpinï¼‰ç™¼ç¾ NAD+ çš„çµæ§‹ç”±å…©å€‹**æ ¸è‹·é…¸** ï¼ˆNucleotideï¼‰çµ„æˆï¼Œå®ƒå€‘æ˜¯æ§‹æˆ DNA çš„æ ¸é…¸çš„çµ„æˆéƒ¨åˆ†ã€‚

ç™¼é…µéç¨‹éœ€è¦é  NAD+ ï¼Œé ç¤ºäº†ç•¶æ™‚æœªä¾†åœ¨å° NAD+ åœ¨äººé¡ä»£è¬éç¨‹ä¸­ç™¼æ®é—œéµä½œç”¨çš„èªè­˜ã€‚

è€Œå®ƒæœƒä»¥å…©ç¨®å½¢å¼å­˜åœ¨ï¼šæ°§åŒ–æ…‹çš„ NAD+ å’Œé‚„åŸæ…‹çš„ NADHã€‚

NAD èˆ‡ NADH çš„é—œä¿‚

## **NAD+ èˆ‡è€åŒ–é—œä¿‚**

åœ¨è¡°è€çš„å°é¼ å’Œç·šèŸ²ä¸­ï¼ŒNAD+ çš„é«”å…§æ¿ƒåº¦éƒ½ä¸‹é™äº†ï¼›å¤§é‡å‹•ç‰©å¯¦é©—é¡¯ç¤ºè£œå…… NR å’Œ NMN ç­‰çš„NAD+ å‰é©…ç‰©ï¼Œèƒ½å¤ èµ·åˆ°å»¶ç·©è¡°è€å’Œå»¶é•·å£½å‘½çš„åŠŸæ•ˆã€‚åœ¨äººé«”è©¦é©—ä¸Šä¹Ÿæœ‰é¡ä¼¼ç™¼ç¾ã€‚

ç²’ç·šé«”åŠŸèƒ½ç•°å¸¸æ˜¯è¡°è€çš„ 9 å¤§æŒ‡æ¨™ä¹‹ä¸€ï¼Œè€Œ NAD+ ä¸è¶³å‰‡æ˜¯å¼•ç™¼é€™ä¸€ç¾è±¡çš„ç½ªé­ç¦é¦–ã€‚

ç´°èƒæ ¸å…§çš„ NAD+ ä¸‹é™æœƒåš´é‡å½±éŸ¿ç²’ç·šé«”ç›¸é—œåŸºå› çš„è¡¨é”ï¼Œè€Œç´°èƒè³ªä¸­çš„ NAD+ å‰‡èƒ½å¤ é€šéèª¿æ§æ°§åŒ–é…¶å’Œé‚„åŸé…¶çš„æ´»æ€§ï¼Œå°ç·šç²’é«”é€²è¡Œä¿è­·ã€‚

é€šé NAD+ è£œå……åŠ‘ç­‰æ–¹å¼æ¢å¾© NAD+ æ¿ƒåº¦ï¼Œèƒ½é¡¯è‘—æ”¹å–„ç²’ç·šé«”åŠŸèƒ½ï¼Œé€™è¡¨ç¤ºèº«é«”ä¸¦æ²’æœ‰æºæºä¸æ–·çš„ NAD+ å¯ä½¿ç”¨ã€‚

å¯¦é©—é¡¯ç¤º NAD+ **å¯¦éš›ä¸Šéš¨è‘—å¹´é½¡çš„å¢é•·è€Œä¸‹é™ã€‚**

NAD éš¨è‘—å¹´é½¡çš„å¢é•·è€Œä¸‹é™

## **ä¸‹é™çš„åŸå› ï¼Ÿ**

NAD éš¨è‘—å¹´é½¡çš„å¢é•·è€Œä¸‹é™01

**ã€Œç©¶ç«Ÿæ˜¯å› ç‚ºåˆæˆä¸å¤ ï¼Œé‚„æ˜¯ç”¨é‡å¤ªå…‡ï¼Ÿã€**

é€™å€‹å•é¡Œå€¼å¾—å»æ€è€ƒï¼Œå¦‚æœæ˜¯åˆæˆä¸å¤ ï¼Œé‚£å¯ä»¥é€éå¤–ä¾†è£œå……ä¾†é”æˆã€‚å¦‚æœæ˜¯ç”¨é‡å¤ªå…‡ï¼Œé€éé¡å¤–è£œå……æ•ˆæœæœƒå—é™ã€‚

é‚£æˆ‘å€‘å¯ä»¥å¾èª¿ç¯€èº«é«”å…§è›‹ç™½è³ªä½¿ç”¨æƒ…æ³ä¾†æ”¹å–„ã€‚

## **å¹´ç´€å¢é•·è®“ NAD+ æ¶ˆè€—å¢åŠ **

é€™å€‹å•é¡Œæœ‰äº†æœ€æ–°çš„è§£ç­”ã€‚

è¥¿å…ƒ 2021 å¹´ 9 æœˆï¼Œç™¼è¡¨æ–¼é ‚å°–é›œèªŒã€Šç´°èƒã€‹çš„å­åˆŠç ”ç©¶è¡¨ç¤ºï¼Œåˆ©ç”¨**åŒä½ç´ æ¨™è¨˜** ï¼ˆIsotope Labellingï¼‰è¿½è¹¤èˆ‡**è³ªè­œæ³•** ï¼ˆMass Spectrometryï¼ŒMSï¼‰æŠ€è¡“ç™¼ç¾è€åŒ–**ä¸¦æœªå¹²æ“¾ NAD+ åˆæˆé€Ÿåº¦ã€‚**

**åå€’æ˜¯å› ç‚ºå¹´ç´€çš„å¢é•·è®“ NAD+ æ¶ˆè€—å¤§å¹…å¢åŠ ** ï¼Œé€™æ‰æ˜¯è€å¹´å°é¼  NAD+ ä¸è¶³çš„æ ¹æœ¬åŸå› ã€‚

ç ”ç©¶é‚„æŒ‡å‡º**ç†±é‡é™åˆ¶** ï¼ˆCalorie Restrictionï¼ŒCRï¼‰èƒ½æ˜é¡¯é™ä½ NAD+ çš„æ¶ˆè€—é€Ÿåº¦ã€‚

ä¸æ˜¯æˆ‘åœ¨å¹æ§ç†±é‡é™åˆ¶ï¼Œè€Œæ˜¯å®ƒçœŸçš„æ˜¯å¾ˆé‡è¦çš„é—œéµã€‚

æœ‰é—œ**ç†±é‡é™åˆ¶** ç ”ç©¶ç™¼å±•ï¼š

ğŸ‘‡ğŸ‘‡ğŸ‘‡ğŸ‘‡ğŸ‘‡ğŸ‘‡ğŸ‘‡ğŸ‘‡ğŸ‘‡ğŸ‘‡

> [é›†æŠ—è¡°è€è¿‘ç™¾å¹´ç ”ç©¶å¤§æˆâ€”å‚³æ‰¿è‡ªç†±é‡é™åˆ¶æ³•ä¹‹ageLOCæŠ€è¡“çš„èª•ç”Ÿ](https://agelocked.com/%e9%9b%86%e6%8a%97%e8%a1%b0%e8%80%81%e8%bf%91%e7%99%be%e5%b9%b4%e7%a0%94%e7%a9%b6%e5%a4%a7%e6%88%90-%e5%82%b3%e6%89%bf%e8%87%aa%e7%86%b1%e9%87%8f%e9%99%90%e5%88%b6%e6%b3%95%e4%b9%8bageloc/)

é€™ç¯‡ç ”ç©¶ç™¼ç¾è€åŒ–æœƒé€ æˆå°é¼ é«”å…§çµ„ç¹”ä¸­ NAD+ ä¸‹é™ï¼Œä¸éã€Œ**é™¤ NMN å¤–ï¼Œå¤šæ•¸ NAD+ å‰é©…ç‰©çš„é‡ä¸¦æœªæ˜é¡¯ä¸‹é™** ã€ã€‚

ã€ŒåŸæ–™ã€æ²’æœ‰å°‘ï¼ŒNAD+ å»ä¸å¤ ç”¨ï¼Œæ¶ˆè€—é€Ÿç‡å»åœ¨é¡¯è‘—ä¸Šå‡ï¼Œé€™åœ¨å…¶ä»–æœŸåˆŠæŒ‡å‡ºå¯èƒ½è·Ÿ **NAD+ å¤šç¨®æ¶ˆè€—é…¶æ´»æ€§éš¨è€åŒ–å¢åŠ ** çš„æœ‰é—œã€‚

åŸä¾†å¦‚æœè¦ä¿æŒæœ€å¤šçš„ NAD+ ï¼Œã€Œç¯€æµã€æ‰æ˜¯é™ä½ NAD+ æ¶ˆè€—çš„é—œéµã€‚

ä¸éæƒ³é™ä½ NAD+ æ¶ˆè€—ï¼Œæˆ‘å€‘é‚„èƒ½é ä»€éº¼ï¼Ÿ

é€šéèª¿ç¯€ NAD+ çš„é™é€Ÿé…¶â€“**ç…™é…°èƒºç£·é…¸æ ¸ç³–åŸºè½‰ç§»é…¶** ï¼ˆNicotinamide phosphoribosyltransferaseï¼ŒNAMPTï¼‰ï¼Œä¸¦èª¿æ§ NAD+ é‡è¦æ¶ˆè€—é…¶ï¼ˆSIRTsã€CD38 èˆ‡ PARPsï¼‰æ´»æ€§ï¼Œé€²è€Œé™ä½ DNA æå‚·ï¼Œè®“ NAD+ ä¿æŒæ‡‰æœ‰çš„æ¿ƒåº¦ã€‚

é€™æ™‚å€™ç†±é‡é™åˆ¶ï¼ˆCRï¼‰åˆå‡ºç¾å•¦ï¼æœ¬æ¬¡ç ”ç©¶ç™¼ç¾å¦‚æœèƒ½è®“å°é¼ çµ‚ç”Ÿç†±é‡é™åˆ¶ï¼Œé™ä½äº†è¡°è€å°é¼ é«”å…§ NAD+ æ¶ˆè€—ã€‚

ç›¸æ¯”è¼ƒå°ç…§çµ„ï¼Œ**ç†±é‡é™åˆ¶** çµ„è€å¹´é¼ é«”å…§è¢«æ¨™è¨˜ NAD+ çš„æ¯”ä¾‹å¤§å¤§é™ä½ï¼Œé€™æ„å‘³åŸæœ‰ NAD+ çš„æ¶ˆè€—è¢«æ¸›ç·©ï¼Œé‡æ–°åˆæˆçš„ NAD+ è¼ƒå°‘ã€‚

ç ”ç©¶è€…èªç‚º NAD+ ä¸‹é™çš„ä¸»è¦åŸå› æ˜¯è¡°è€å½±éŸ¿åˆæˆï¼Œæœ¬æ¬¡ç ”ç©¶åœ¨é‡åŒ–ç”Ÿç‰©é«”ä¸­å¤šéƒ¨ä½çš„çµ„ç¹”é‡æ¸¬ NAD+ å¾Œï¼Œæå‡ºå¹´é½¡å¢é•·å°è‡´çš„æ¶ˆè€—ä¸Šå‡æ‰æ˜¯å½±éŸ¿ NAD+ æ¿ƒåº¦çš„é—œéµåŸå› ã€‚

é‚£æˆ‘å€‘å¦‚æœè¦æŠ—è¡°è€ï¼Œå°±è¦å¾€ NADï¼‹ è‘—æ‰‹ã€‚

## **æé«˜ç”Ÿç‰©é«”å…§ NADï¼‹ çš„æ–¹æ³•ï¼š**

### **ç¬¬ä¸€ç¨®ã€æå‡ NAD+ æ´»æ€§**

é‹å‹•ã€ç¦é£Ÿå’Œç†±é‡é™åˆ¶å¯ä»¥å•Ÿå‹•ç”Ÿç‰©èƒ½é‡ä»£è¬ä¸­çš„é—œéµåˆ†å­â€“**å–®ç£·é…¸è…ºè‹·æ´»åŒ–è›‹ç™½è³ªæ¿€é…¶** ï¼ˆAMP activated Protein Kinaseï¼ŒAMPKï¼‰ï¼Œè€Œ AMPK æ´»æ€§å¢å¼·å¯ä»¥æé«˜ NAD+ çš„ç”Ÿç‰©åˆ©ç”¨åº¦ã€‚

æ­¤å¤–ï¼Œé‹å‹•é‚„å¯èª˜å°ç´°èƒå…§ NAD+ åˆæˆï¼Œæœ€çµ‚ä¹Ÿèƒ½æé«˜ NAD+ çš„ç”Ÿç‰©åˆ©ç”¨åº¦ã€‚

### **ç¬¬äºŒç¨®ã€è£œå…… NAD+ å‰é©…ç‰©**

äººé¡é€šå¾é£²é£Ÿä¸­ç²å–æ°¨åŸºé…¸ï¼Œé€™äº›æ°¨åŸºé…¸æ˜¯åˆæˆ NAD+ çš„ææ–™ã€‚ä¸éé€™æ¨£æ•ˆç‡ä¸ä½³ï¼Œäººå€‘æƒ³ç›´æ¥å£æœ NAD+ ã€‚

ä½†æ˜¯å£æœ NAD+ ç„¡æ³•è¢«äººé«”å¸æ”¶ï¼Œæ‰€ä»¥ç ”ç©¶äººå“¡é›†ä¸­æŠŠç²¾åŠ›æ”¾åœ¨è£œå…… NAD+ å‰é©…ç‰©çš„æ–¹æ³•ï¼Œä¾†å¢åŠ å…§æºæ€§ NAD+ çš„åˆæˆã€‚

NADçš„å‰é©…ç‰©æœ‰ï¼š

NAD åˆæˆè·¯å¾‘

#### **è£œå……è¸é¹¼é†¯èƒºå–®æ ¸è‹·é…¸ï¼ˆNicotinamide Mononucleotideï¼ŒNMNï¼‰**

ç ”ç©¶é¡¯ç¤ºé•·æœŸä½¿ç”¨ NMN å¯ä»¥é¡¯è‘—æé«˜å°é¼ é«”å…§ NAD+ æ¿ƒåº¦ï¼Œå»¶é•·å£½å‘½ï¼Œä¸¦æé«˜è€å¹´å°é¼ çš„å…¨èº«èƒ°å³¶ç´ æ•æ„Ÿæ€§ï¼Œèƒ½é‡ä»£è¬å’Œé«”åŠ›æ´»å‹•ï¼Œæ”¹å–„è„‚è³ªåˆ†ä½ˆï¼Œå¢å¼·äº†å¹¾ä¹æ‰€æœ‰å™¨å®˜çš„ç·šç²’é«”åŠŸèƒ½ï¼Œé™ä½æ°§åŒ–å£“åŠ›ï¼Œå¤§å¹…æ”¹å–„è¡°è€å¼•èµ·çš„ç¥ç¶“å•é¡Œå’ŒèªçŸ¥åŠŸèƒ½ã€‚

ä¸€é …é‡å°æ—¥æœ¬ç”·æ€§çš„ç ”ç©¶ç™¼ç¾ï¼Œå–®æ¬¡å£æœæœ€é«˜ 500 mg çš„ NMN å¾Œæ²’æœ‰å®‰å…¨å•é¡Œã€‚ åœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç§‘å­¸å®¶ç™¼ç¾å¿ƒç‡ã€è¡€å£“ã€æ°§é£½å’Œåº¦æˆ–é«”æº«æ²’æœ‰è®ŠåŒ–ã€‚

#### **è£œå……è¸é¹¼é†¯èƒºæ ¸ç³–ï¼ˆNicotinamide Riboseï¼ŒNRï¼‰**

æ”å– NR èƒ½æ”¹å–„ç‡Ÿé¤Šä¸è‰¯å°é¼ çš„ç²’ç·šé«”ä»£è¬èˆ‡è‚Œè‚‰å¹¹ç´°èƒåŠŸèƒ½ï¼Œå»¶é•·å°é¼ çš„å£½å‘½ã€‚

NR çš„é‹è¼¸æ©Ÿåˆ¶ç›®å‰ç›¸å°æ¸…æ¥šï¼Œå®ƒå¯ä»¥ç›´æ¥é€šé**å¹³è¡¡å‹æ ¸è‹·è½‰é‹è›‹ç™½** ï¼ˆEquilibrative Nucleoside Transportersï¼ŒENTsï¼‰è¢«è½‰å…¥ç´°èƒï¼Œä¸¦è¢«ä»£è¬ç‚º NMN å¾Œå†è½‰åŒ–ç‚º NAD+ã€‚

NMNèˆ‡NRé€²å…¥ç´°èƒé€”å¾‘

ä¸€é …å°äººé«”æœç”¨ NR çš„ç ”ç©¶ç™¼ç¾ï¼Œåœ¨è¶…é‡ä½†å…¶ä»–æ–¹é¢å¥åº·çš„ç”·æ€§å’Œå¥³æ€§ä¸­ï¼Œç§‘å­¸å®¶å€‘çµ¦äºˆé€™äº›å—è©¦è€…åœ¨ 8 é€±å…§é«˜é” 1000 mg /å¤© çš„åŠ‘é‡ï¼Œ NR ä»‹å…¥åœ¨é•·æœŸçµ¦è—¥å¾Œæ²’æœ‰å®‰å…¨å•é¡Œã€‚

åœ¨äººé«”è‡¨åºŠè©¦é©—ä¸­ï¼Œå¤§éƒ¨åˆ†éƒ½è¡¨æ˜ NR èƒ½æå‡è¡€æ¶²çš„ NAD+ ï¼Œä½†ä¸èƒ½æå‡è‚Œè‚‰ä¸­çš„ NAD+ æ¿ƒåº¦ã€‚

åœ¨å‹•ç‰©è©¦é©—ä¸­ç²å¾—çš„é—œæ–¼èƒ½é‡ä»£è¬ã€èƒ°å³¶ç´ èª¿ç¯€å’Œå¿ƒè‚ºåŠŸèƒ½çš„æ­£é¢æ•ˆæœï¼Œä½†æ˜¯å°‘æœ‰èƒ½åœ¨äººé«”è©¦é©—ä¸­å¾—åˆ°é‡è¤‡çš„ã€‚

#### **è£œå……è¸é¹¼é†¯èƒºï¼ˆNicotinamideï¼ŒNAMï¼‰**

è¸é¹¼é†¯èƒºæ˜¯**è¸é…¸** ï¼ˆNiacinï¼ŒNAï¼‰çš„é†¯èƒºã€‚

å®ƒä½œç‚º NAD+ è£œæ•‘é€”å¾‘ä¸­çš„ç›´æ¥å‰é©…ç‰©ï¼Œä¹Ÿæ˜¯ NAD+ åˆ†è§£ä»£è¬çš„å‰¯ç”¢ç‰©ã€‚

åœ¨å°ç§€éº—ç·šèŸ²çš„å¯¦é©—ä¸­æ·»åŠ  NAM è™•ç†å¾Œï¼Œå£½å‘½æ˜é¡¯å»¶é•·ï¼Œä½†æ˜¯é«˜åŠ‘é‡çš„ NAM åè€Œæœƒä½¿é…µæ¯å’Œç§€éº—ç·šèŸ²çš„å£½å‘½ç¸®çŸ­ã€‚

æ‰€ä»¥ï¼Œé‡å° NAM å°æŠ—è¡°è€çš„å¥½è™•ç›®å‰é‚„éœ€è¦æ›´å¤šçš„å¯¦é©—é©—è­‰ã€‚

### **ç¬¬ä¸‰ç¨®ã€æ¸›å°‘ NAD+ æ¶ˆè€—**

å¦‚æœèƒ½é™ä½ NAD+ çš„æ¶ˆè€—ï¼Œç›¸å°çš„å°±æ˜¯èƒ½ç•™ä½æ›´å¤šçš„ NAD+ã€‚

ç›®å‰æ¸›å°‘ NAD+ æ¶ˆè€—çš„ç­–ç•¥ä¸»è¦é›†ä¸­æ–¼æŠ‘åˆ¶ PARPs å’Œ CD38ï¼Œä¿ç•™ NAD+ çµ¦ SIRTs ä½¿ç”¨ã€‚

é€™ä¸‰ç¨®è›‹ç™½åˆ†åˆ¥ä½œç”¨ç‚ºï¼š

**â‘ PARPsï¼ˆPoly-ADP-ribose Polymerasesï¼‰è›‹ç™½å®¶æ—**  
  
èƒ½å°æ—©æœŸ DNA æå‚·ä½œå‡ºåæ‡‰ï¼Œæœƒå•Ÿå‹•å—æéƒ¨ä½çš„DNAä¿®å¾©ã€‚å› æ­¤ï¼Œè‹¥PARPsæŒçºŒç¶­æŒé«˜æ´»æ€§ï¼Œæœƒé€ æˆ NAD+ çš„è€—ç«­ã€‚å…¶ä¸­ä»¥ PARP-1 ç‚ºæœ€ä¸»è¦çš„æ¶ˆè€—è€…ã€‚

**â‘¡CD38 èˆ‡ CD157** æ˜¯ä¸€ç¨®**ç’° ADP æ ¸ç³–æ°´è§£é…¶** ï¼ˆcyclic ADP-ribose hydrolase ï¼‰ï¼›  
  
CD38 ä»¥ NAD+ èˆ‡ NMN ç‚ºèµ·å§‹ç‰©ï¼Œæ¿€æ´» Ca2+ ä¿¡è™Ÿä¸¦èª¿ç¯€å¿…è¦çš„ç´°èƒéç¨‹ï¼ˆå¦‚å…ç–«ç´°èƒæ¿€æ´»ã€ç”Ÿå­˜å’Œä»£è¬ï¼‰ã€‚è€ŒCD157å‰‡ä»¥ NAD+ èˆ‡ NR ä½œç‚ºèµ·å§‹ç‰©ï¼Œåœ¨è¡°è€çµ„ç¹”ä¸­è¡¨é”ä¸Šèª¿ã€‚

**â‘¢SIRTsï¼ˆSirtuinsï¼‰è›‹ç™½å®¶æ—**  
  
æ˜¯ä¸€ç¨®é€²åŒ–ä¸Šé«˜åº¦ä¿å®ˆçš„**çµ„è›‹ç™½å»ä¹™é†¯é…¶** ï¼ˆHistone Deacetylasesï¼ŒHDACï¼‰ï¼Œåœ¨äººé¡ä¸­ç™¼ç¾äº† 7 ç¨®ï¼Œåˆ†åˆ¥åç‚º SIRT 1~7ã€‚å®ƒå€‘æ¶ˆè€— NAD+ ä¾†ä¿®å¾© DNAã€å»¶é•·ç´°èƒå£½å‘½ã€æ”¹å–„èº«é«”ä»£è¬èƒ½åŠ›ã€‚

### **ç¬¬å››ç¨®ã€å¢åŠ  NAD+ åˆæˆèƒ½åŠ›**

**ç´°èƒå¤–è¸é¹¼èƒºç£·é…¸æ ¸ç³–åŸºè½‰ç§»é…¶** ï¼ˆextracellular Nicotinamide Phosphoribosyltransferaseï¼ŒeNAMPTï¼‰æ˜¯è£½é€  NAD+ çš„é‡è¦é…µç´ ã€‚

ä¸€ç¯‡å°é¼ ç ”ç©¶è¡¨æ˜åªé æ³¨å°„å¤–æºçš„ NAMPT å¯ä»¥æœ‰æŠ—è¡°è€ä»¥åŠå»¶é•·å£½å‘½çš„æ•ˆæœï¼Œä¹Ÿæœ‰ä¸€ç¯‡ç ”ç©¶é–‹å§‹èƒ½æ¿€æ´» NAMPT çš„å°åˆ†å­ã€‚

ä½†æ³¨å°„å¤–æºè›‹ç™½è³ªå’Œæ–°åˆ†å­çš„é¢¨éšªéƒ½å¤ªå¤§ï¼Œè€Œä¸”ç›¸é—œç ”ç©¶å­˜åœ¨è¨±å¤šçˆ­è­°å’ŒçŸ›ç›¾çµæœï¼Œæ‰€ä»¥é€™æ¢è·¯ç›®å‰æœ‰å¾…æ›´å¤šè­‰æ“šä¾†è­‰æ˜ã€‚

**NAD+ å‰é©…ç‰©å¾ˆå¤šç¨®ï¼Œè£œå“ªå€‹æŠ—è¡°è€æ•ˆæœå¥½ï¼Ÿ**

ç›®å‰ä¾†èªªï¼Œ**ä»¥ NMN è¨è«–èˆ‡è‡¨åºŠå¯¦é©—æœ€å¤š** ã€‚

nmnç”¢å“

å‹•ç‰©å¯¦é©—åšéäº†ï¼Œè­‰æ˜å¯è¡Œæ€§ã€‚æ¥ä¸‹ä¾†å°±æ˜¯å¾€è‡¨åºŠç ”ç©¶èµ°ä¸‹å»ã€‚

ä¸éå‹•ç‰©å¯¦é©—çµæœå¾ˆå¥½ï¼Œä¸ä»£è¡¨äººé«”è‡¨åºŠç ”ç©¶å°±æœƒæˆåŠŸã€‚æˆ‘å€‘ä¾†çœ‹å„åœ‹æœ€æ–°çµæœã€‚

## **ç¾åœ‹è‡¨åºŠç ”ç©¶**

åœ¨ã€Šç§‘å­¸ã€‹æœŸåˆŠä¸Šï¼Œç™¼è¡¨äº†å…¨çƒé¦–å€‹äººé«”è‡¨åºŠå¯¦é©—çš„çµæœã€‚

ä¸€ä»½ä¾†è‡ªç¾åœ‹çš„ç ”ç©¶æ¡ç”¨äº†å®‰æ…°åŠ‘å°ç…§ã€éš¨æ©Ÿã€é›™ç›²çš„æ©Ÿåˆ¶æ–¹æ³•ï¼Œæ”¶é›†äº† 13 åä¸­å¹´ã€æ‚£æœ‰è‚¥èƒ–ä¸”å·²åœç¶“çš„å©¦å¥³ï¼Œæ¯æ—¥åœ¨è‡ªå·±çš„æ—©é¤ä¸­åŠ å…¥äº†å…©é¡† 125 mg çš„ NMN è† å›Šï¼ˆå…± 250 mgï¼‰ã€‚

åœ¨æœç”¨ 10 é€±å¾Œï¼Œç ”ç©¶äººå“¡å°åƒèˆ‡è€…çš„ç”Ÿç†ç‹€æ…‹é€²è¡Œè©³ç´°çš„æª¢æŸ¥ã€‚

æœç”¨ NMN å¾Œï¼Œåƒèˆ‡è€…è‚Œè‚‰ä¸­å› ç‚ºè¡°è€æ‰€åš´é‡é™ä½çš„èƒ°å³¶ç´ æ•æ„Ÿæ€§ï¼Œå¾—åˆ°äº† 25 % çš„æå‡ã€‚å¾ŒçºŒçš„ RNA åˆ†æä¸­ï¼Œç™¼ç¾ç«Ÿç„¶å—è©¦è€…é«”å…§æœ‰ 308 ç¨®åŸºå› çš„è¡¨é”è¢«æ”¹è®Šäº†ã€‚

ä¸éå¯æƒœçš„æ˜¯ï¼ŒNMN æ²’æœ‰å°äººé«”çš„è‚Œè‚‰åŠ›é‡ã€è€åŠ›ã€ç–²å‹æ¢å¾©é€Ÿåº¦é€ æˆä»»ä½•æå‡ã€‚

é›–ç„¶è‚Œè‚‰çš„èƒ°å³¶ç´ æ•æ„Ÿæ€§æå‡äº†ï¼Œä¸éå¾é«”é‡åˆ°é«”è„‚ç‡ï¼Œå¾è¡€å£“åˆ°è¡€ç³–ï¼Œå¾èƒ°å³¶ç´ æ°´å¹³åˆ°ç³–åŒ–è¡€ç´…è›‹ç™½å’Œç”˜æ²¹ä¸‰é…¯ï¼Œæ‰€æœ‰èˆ‡ä»£è¬è¡°è€çš„æŒ‡æ¨™å…¨éƒ½æ²’æœ‰å‡ºç¾çµ²æ¯«è®ŠåŒ–ï¼Œä¹Ÿæ²’æœ‰å°ç²’ç·šé«”åŠŸèƒ½ç”¢ç”Ÿä»»ä½•æ”¹è®Šã€‚

## **æ—¥æœ¬è‡¨åºŠç ”ç©¶**

æ—¥æœ¬æ±äº¬å¤§å­¸ä¹Ÿå®Œæˆ NMN çš„äººé«”è‡¨åºŠè©¦é©—ã€‚

åœ¨ã€Šè‡ªç„¶é€šè¨Šã€‹æœŸåˆŠä¸Šï¼Œé€™é …ç ”ç©¶æ¡ç”¨äº†å®‰æ…°åŠ‘å°ç…§ã€éš¨æ©Ÿã€é›™ç›²çš„æ©Ÿåˆ¶æ–¹æ³•ï¼Œæ”¶é›†äº† 20 ä½ 65 æ­²ä»¥ä¸Šçš„å¥åº·è€å¹´ç”·æ€§ï¼Œé€²è¡Œäº†ç‚ºæœŸ 6 é€±æˆ– 12 é€±çš„ 250 mg / å¤©çš„ NMN æ·»åŠ å¯¦é©—ã€‚

èˆ‡æœç”¨ NMN ä¹‹å‰ç›¸æ¯”ï¼Œé•·è¼©å€‘çš„æ­¥æ…‹é€Ÿåº¦å’Œæ¡åŠ›é¡¯è‘—æå‡ï¼Œå³é‚Šè½è¦ºæ¸¬è©¦ä¹Ÿæ”¹å–„ã€‚

è€Œå®‰æ…°åŠ‘çµ„çš„å°ç…§çµæœå‰‡è­‰å¯¦ï¼Œä»–å€‘èº«é«”çš„æ”¹è®Šè¦æ­¸åŠŸæ–¼ NMNã€‚

ä¸éé€™ç¯‡æ¸¬è©¦äº†å—è©¦è€…å¤šè™•å…§è‡Ÿè„‚è‚ªåˆ†ä½ˆçš„è®ŠåŒ–ï¼Œçµæœæ˜¯ã€Œæ²’æœ‰è®ŠåŒ–ã€ã€‚

å¦å¤–åœ¨**å£æœè‘¡è„ç³–è€é‡è©¦é©—** ï¼ˆOral Glucose Tolerance Testï¼ŒOGTTï¼‰é¡¯ç¤ºï¼šèˆ‡èƒ°å³¶ç´ æ•æ„Ÿæ€§é—œè¯çš„**èƒ°å³¶ç´ é˜»æŠ—æª¢æ¸¬** ï¼ˆHomeostasis Model Assessment-Insulin Resistance indexï¼ŒHOMA-IRï¼‰ã€**è„‚è¯ç´ ** ï¼ˆAdiponectinï¼‰ã€**ç™½ç´°èƒä»‹ç´ -6** ï¼ˆInterleukin 6ï¼ŒIL-6ï¼‰ç­‰æŒ‡æ¨™ï¼Œåœ¨æœç”¨ NMN å‰å¾Œå¹¾ä¹æ²’ä»€éº¼å·®ç•°ã€‚

å¦å¤–ä¸€ç¯‡åœ¨è¥¿å…ƒ 2022 å¹´ 2 æœˆçš„ã€Šç‡Ÿé¤Šã€‹æœŸåˆŠç™¼è¡¨äº†çµæœé¡¯ç¤ºï¼Œä½œè€…æ‹›å‹Ÿäº† 108 ä½ 65 æ­²ä»¥ä¸Šçš„å¥åº·è€å¹´äººå—è©¦è€…ï¼ŒæŠŠä»–å€‘åˆ†æˆ 4 çµ„ï¼Œåˆ†åˆ¥å°æ‡‰ï¼š

ä¸Šåˆ 12 é»ä»¥å‰åƒ 250 mg çš„ NMNã€ä¸Šåˆ 12 é»ä»¥å‰åƒå®‰æ…°åŠ‘ã€ä¸‹åˆ 6 é»ä»¥å¾Œåƒ 250 mg çš„ NMN å’Œä¸‹åˆ 6 é»ä»¥å¾Œåƒå®‰æ…°åŠ‘ã€‚

é€™å€‹è‡¨åºŠå¯¦é©—æ¡ç”¨éš¨æ©Ÿã€é›™ç›²ã€å®‰æ…°åŠ‘å°ç…§çš„æ¨™æº–åšæŒçºŒ 12 å€‹æ˜ŸæœŸï¼Œä¸¦ä¸”ç”±æ—¥æœ¬ä¸‰è±å•†äº‹ç”Ÿå‘½ç§‘å­¸æ ªå¼æœƒç¤¾è´ŠåŠ©æä¾›äº†æ¸¬è©¦ç”¨çš„è—¥å“ã€‚

çµæœé¡¯ç¤ºæ¯å¤©æœç”¨ 250mg NMN é•·é” 12 å‘¨ï¼Œç„¡è«–æ˜¯ä¸Šåˆï¼ˆèµ·åºŠåˆ°12é»ä¹‹å‰ï¼‰é‚„æ˜¯ä¸‹åˆï¼ˆä¸‹åˆ6é»åˆ°ç¡è¦ºä¹‹å‰ï¼‰æœç”¨ï¼Œå°ç¡çœ å“è³ªéƒ½æ²’æœ‰é¡¯è‘—æ”¹å–„ã€‚é€™é‡Œçš„ç¡çœ å“è³ªåŒ…æ‹¬ç¡çœ æ™‚é–“ã€ç¡çœ å»¶é²ã€ç¡çœ è—¥ç‰©æŒ‡æ•¸ã€ç¡çœ å¹²æ“¾æŒ‡æ•¸ã€ç™½å¤©ç´Šäº‚æŒ‡æ•¸ã€ç¡çœ å“è³ªæŒ‡æ•¸ã€ç¡çœ æ•ˆç‡èˆ‡ç¸½ PSQI æŒ‡æ•¸ç­‰ã€‚

å¦å¤–åœ¨æ”¹å–„ç²¾åŠ›çš„æ¸¬è©¦ä¸­ï¼Œåƒ…ä¸‹åˆæœç”¨ NMN å¯ä»¥é¡¯è‘—æ”¹å–„å—œç¡æ„Ÿï¼Œä½†å¹…åº¦åƒ…æ¯”å®‰æ…°åŠ‘ç•¥é«˜ã€‚

ä¸Šåˆæœç”¨ NMN å°æ–¼å—œç¡æ„Ÿçš„é™ä½ä¸å¦‚å®‰æ…°åŠ‘ã€‚å…¶ä»–æ¸¬è©¦çš„é …ç›®åŒ…æ‹¬ä¸ç©©å®šæ€§ã€ä¸å®‰æ„Ÿã€é²éˆæ„Ÿã€çœ¼ç–²å‹å’Œç¸½ç–²å€¦æŒ‡æ•¸å‡ç„¡é¡¯è‘—æ”¹å–„ã€‚

## **ä¸­åœ‹è‡¨åºŠç ”ç©¶**

ä¸­åœ‹ä¹Ÿæœ‰ä¸€é … NMN è‡¨åºŠç ”ç©¶æˆæœã€‚

é€™é …ç ”ç©¶æ¡ç”¨äº†å®‰æ…°åŠ‘å°ç…§ã€éš¨æ©Ÿã€é›™ç›²çš„æ©Ÿåˆ¶æ–¹æ³•ï¼Œå¯¦é©—ä¸­æ”¶é›†å—è©¦è€… 48 äººè·‘è€…ç‚ºæœŸ 6 é€±ï¼Œå—è©¦è€…åˆ†ç‚ºå››çµ„ï¼šä½åŠ‘é‡çµ„ï¼ˆ300 mg / å¤©ï¼‰ã€ä¸­åŠ‘é‡çµ„ï¼ˆ 600 mg / å¤© )ã€é«˜åŠ‘é‡çµ„ï¼ˆ1200 mg / å¤©ï¼‰èˆ‡å°ç…§çµ„ã€‚åƒèˆ‡è€…é™¤äº†æ¯å¤©éœ€è¦å£æœ NMN å¤–ï¼Œé‚„è¢«è¦æ±‚é€²è¡Œæ¯é€±5 ~ 6 æ¬¡æ¯æ¬¡ 40 ~ 60 åˆ†é˜çš„è¨“ç·´ã€‚

NMN å¯ä»¥å°‡å®Œå…¨å¥åº·çš„ä¸­å¹´äººçš„**ç¬¬ä¸€æ›æ°£é–¾å€¼** ï¼ˆ1st Ventilatory Thresholdï¼ŒVT1ï¼‰å’Œ**ç¬¬äºŒæ›æ°£é–¾å€¼** ï¼ˆ2nd Ventilatory Thresholdï¼Œ VT2ï¼‰é€™å…©å€‹èƒ½ç›´æ¥åæ˜ äººé«”é‹å‹•èƒ½åŠ›çš„æŒ‡æ¨™æå‡åˆ°éå¸¸é«˜ã€‚

çµåˆ**æ°§æ°£æ¶ˆè€—** ï¼ˆVO2ï¼‰å’Œ**æœ€å¤§æ”æ°§é‡** ï¼ˆVO2 Maxï¼‰æª¢æ¸¬æ•¸æ“šï¼Œç ”ç©¶äººå“¡èªç‚ºé€™ç¨®ã€Œé«”èƒ½ã€æå‡çš„åŸå› æ˜¯å› ç‚º NMN å°äººé«”éª¨éª¼è‚Œçš„æ°§æ°£åˆ©ç”¨èƒ½åŠ›é€²è¡Œäº†å¼·åŒ–ï¼Œä½¿å¾—è‚Œè‚‰çš„æŒä¹…åŠ›å’Œæ•´é«”åŠŸèƒ½å¾—åˆ°äº†å¤§å¹…æå‡ã€‚

## **å¤¢ç¢**

è¿‘ 40 å¹´ä¾†ç›¼æœ›çš„ã€Œ **NMN é€²å…¥ç´°èƒå¾Œè½‰åŒ–ç‚º NAD+ï¼Œç„¶å¾Œ NAD+ æ¿€æ´»é€™å€‹æ¿€æ´»é‚£å€‹ï¼Œé€†è½‰è¡°è€** ã€ã€‚

ä½†æœ€è¿‘å„åœ‹çš„è‡¨åºŠå¯¦é©—çµæœä¸¦**ä¸æ”¯æŒ** é€™é …å‡èªªæ³•ï¼Œåƒ…é  NAD+ï¼Œé‚„ä¸èƒ½å®Œå…¨è§£é‡‹æŠ—è¡°è€åŠŸæ•ˆã€‚

ä¸éå¦‚æœé™åˆ¶ç¯„åœåœ¨ã€Œ**éª¨éª¼è‚Œçš„ç¶­æŒèˆ‡æŠ—è¡°è€** ã€é€™éƒ¨åˆ†ï¼Œå¯ä»¥èªªé€™æ˜¯ä¸€å€‹æ¯”è¼ƒå¥½çš„æ–¹æ³•ï¼Œä¹Ÿæ˜¯ç¾ä»£äººè‚Œå°‘ç—‡çš„ä¸€å€‹è§£æ–¹ã€‚

å¦‚æœæƒ³é æœç”¨ NMN ä¹‹é¡çš„ä¿å¥å“ä¾†ã€Œ**å…¨èº«æ€§æŠ—è¡°è€** ã€çš„è©±ï¼Œæˆ‘æœƒèªªå¤¢è©²é†’äº†ã€‚

## **æ³¨æ„ï¼ä½ è²·åˆ°çš„çœŸçš„æ˜¯ NMN å—ï¼Ÿ**

NMN ç”¢å“ä¹Ÿè¢«ç¨±ä½œ NAD+ ç”¢å“è£œå……åŠ‘ï¼Œæ²’éŒ¯å§ï¼ç„¶è€Œã€Œ NAD+ ç”¢å“è£œå……åŠ‘ã€ä¸¦ä¸è¡¨æ˜¯ä»–è³£çš„ç”¢å“å°±ä¸€å®šæ˜¯ NMN ç”¢å“ï¼Œ

**å› ç‚º NAD+ çš„å‰é©…ç‰©ä¸¦ä¸åªæœ‰ NMN ä¸€ç¨®ã€‚**

æœ¬ä¾†é€™åªæ˜¯ä¸€ä»¶å¾ˆæ™®é€šçš„äº‹æƒ…ï¼Œå¦‚æœå» å•†æ–‡å­—æ¸¸æˆ²èª¤å°æ¶ˆè²»è€…ï¼Œä¸å°å¿ƒå»å› ç‚ºé€™ä¸€æ¦‚å¿µè€Œè¸©é›·å°±ä¸å¥½äº†ã€‚

è€Œä¸”æ›´æ…˜çš„æ˜¯ï¼Œæ ¹æ“š ChromaDex ï¼ˆä¹Ÿå°±æ˜¯é¦™æ¸¯é¦–å¯Œæå˜‰èª æŠ•è³‡çš„é€™å®¶ï¼‰å…¬å¸æŒ‡æ§ï¼Œåœ¨ Amazon ä¸Šå¸‚å ´éŠ·å”®æœ€é«˜çš„ 22 å€‹ NMN å“ç‰Œï¼ˆæˆªè‡³ 2021 å¹´å¹´ä¸­ï¼‰æ¥å—äº†[æ•ˆåŠ›æ¸¬è©¦](https://s23.q4cdn.com/937095816/files/doc_downloads/2021/Quantitative-Analysis-of-22-NMN-Consumer-Products-Oct-2021.pdf)ã€‚

  * 14% çš„ NMN å«é‡ç­‰æ–¼æˆ–é«˜æ–¼æ¨™ç±¤è²æ˜ã€‚
  * 23% çš„ NMN å«é‡ç•¥ä½æ–¼æ¨™ç±¤è¦æ±‚ï¼›æˆ–æ¨™ç±¤è²æ˜çš„ 88-99%ã€‚
  * 64% çš„ NMN å«é‡ä½æ–¼æ–¹æ³•å ±å‘Šé™æˆ–æª¢æ¸¬é™ï¼ˆè¡¨æ˜å­˜åœ¨å°‘æ–¼ 1% çš„è²ç¨± NMNï¼‰
  * 14% çš„ç”¢å“ä¸­æœªæª¢æ¸¬åˆ° NMNã€‚

æ ¹æ“šé€™é …ç ”ç©¶ï¼Œäººå€‘å¯èƒ½åœ¨ç¶²ä¸Šè³¼è²·çš„å¤§å¤šæ•¸ç”¢å“éƒ½å«æœ‰å°‘é‡çš„ NMNï¼Œå› æ­¤è©²åŠ‘é‡ä¸æœƒå¸¶ä¾†è‡¨åºŠç›Šè™•ã€‚

è²·åˆ°ä¸ç´”çš„NMN

æª¢æ¸¬å ±å‘Šçš„çµæœï¼š  
BRLï¼ˆBellow Reporting Limitï¼›Reporting Limit ã€ˆ 1% Label Claimï¼‰ï¼šä½æ–¼æª¢æ¸¬è‡¨ç•Œï¼ˆå°æ–¼æ¨™ç°½å®£ç¨±åŠ‘é‡çš„ 1%ï¼‰  
NDï¼ˆNot Detectedï¼‰ï¼šå®Œå…¨ç„¡æ³•æª¢æ¸¬åˆ°

## **æ‰“ç ´å±€é¢çš„è®Šæ•¸**

ä¸éé€™å€‹å±€é¢å¯èƒ½æœƒè¢«æ¥ä¸‹ä¾†çš„æƒ…æ³çµ¦æ‰“ç ´ã€‚è¥¿å…ƒ 2021 å¹´ å¤šå®¶åª’é«”å ±å°æŒ‡å‡ºï¼Œ[MetroBiotech æ­£åœ¨å’Œ**ç¾åœ‹ç‰¹ç¨®ä½œæˆ°å¸ä»¤éƒ¨** ï¼ˆUnited States Special Operations Commandï¼ŒSOCOMï¼‰åˆä½œæŠ—è¡°è€è—¥ç‰©æ¸¬è©¦](https://www.genengnews.com/news/u-s-special-operations-command-to-test-anti-aging-pill/)ã€‚

è‡ªè¥¿å…ƒ 2018 å¹´é–‹å§‹ä»¥ä¾†ï¼ŒSOCOM å·²ç¶“èŠ±è²»äº† 280 è¬ç¾å…ƒç”¨æ–¼æŠ—è¡°è€å·¥ä½œç ”ç©¶ä¸Šã€‚

ç¾åœ‹ç‰¹ç¨®éƒ¨éšŠè©¦ç”¨æŠ—è€è—¥ç‰©

MetroBiotech çš„ä¸»è¦å€™é¸è—¥ç‰© MIB-626 æ˜¯è©²å…¬å¸è¡¨ç¤ºå·²è¨­è¨ˆã€åˆæˆå’Œç¯©é¸å‡ºæœ€ä½³æ²»ç™‚ç‰¹æ€§çš„ 100 å¤šç¨®æ–°å‹ NAD+ å¢å¼·åŠ‘ä¹‹ä¸€ã€‚è€Œä¸»è¦å€™é¸è—¥ç‰© MIB-626 èˆ‡ NMN æœ‰é—œã€‚

## **ä»¥å¾Œé‚„èƒ½è²·åˆ° NMN å—ï¼Ÿ**

è¥¿å…ƒ 2021å¹´ 9 æœˆï¼Œ Metrobiotech å…¬å¸ï¼ˆä¹Ÿå°±æ˜¯è¾›å…‹èŠæ•™æˆå‰µç«‹çš„é€™å®¶ï¼‰å‘ FDA ç™¼ä¿¡ï¼Œå‘¼ç±²å°æ–¼æ‰€æœ‰çš„ã€Œ NAD+ ç”¢å“è£œå……åŠ‘ã€çš„å¯©æ ¸æ¨™æº–æ‡‰è©²åƒå°å¾… N-ä¹™é…°åŠèƒ±æ°¨é…¸ï¼ˆ NACï¼‰ä¸€æ¨£ï¼Œå¸Œæœ›æŠŠå¸‚é¢ä¸Šæ‰€æœ‰çš„ NAD+ ç”¢å“è£œå……åŠ‘ç•¶åšã€Œ**è—¥å“** ã€ç®¡ç†ä¸¦ä¸‹æ¶æ‰€æœ‰çš„ NAD+ è£œå……åŠ‘ç”¢å“ã€‚

MetroBiotechçµ¦FDAä¿¡çš„å…§å®¹

å› ç‚ºä»–å€‘å…¬å¸ç ”ç™¼çš„è—¥ç‰©ã€ŒMIB-626ã€å®£ç¨±ç‚ºã€Œ è¼”åŠ© NAD+ ç”¢ç”Ÿã€çš„è—¥å“å·²é€²å…¥è‡¨åºŠäºŒæœŸï¼Œå…¶ä»–å…¬å¸éƒ½ä¸å…è¨±è²©å”®ã€‚

MIB-626

é€™æœ‰å¤šåš´é‡å‘¢ï¼Ÿ

åœ¨ç¾åœ‹çš„ä¿å¥å“å¸‚å ´ä¸­ï¼ŒNAC ç¶“å¸¸è¢«ä½œç‚ºç·©è§£å®¿é†‰çš„ç”¢å“ä¾†å”®è³£ï¼Œé€™åœ¨ FDA çœ¼ä¸­å±¬æ–¼åš´é‡åœ°æ“¦é‚Šçƒè¡Œç‚ºã€‚

**å¦‚æœæœ‰å·²ç¶“è¢«åˆ—å…¥è—¥ç‰©çš„æˆåˆ†è¢«ç•¶åšè†³é£Ÿè£œå……åŠ‘ä½¿ç”¨ï¼Œæˆ–è€…è†³é£Ÿè£œå……åŠ‘å®£ç¨±è—¥ç‰©åŠŸæ•ˆçš„è©± FDA é‚„æ˜¯æœƒé‡æ‹³å‡ºæ“Šçš„ã€‚**

é—œæ–¼ FDA å¯ä»¥çœ‹é€™ç¯‡æ–‡ç« ï¼š

> [FDA Approved å°±æ˜¯æ›ä¿è­‰äº†å—ï¼Ÿä¸è¦å†ä¿¡å» å•†èªªä»–å€‘æ˜¯ FDA Approved èªè­‰é€™ä¸€å¥—äº†ï¼](https://agelocked.com/fda-approved-%e5%b0%b1%e6%98%af%e6%8e%9b%e4%bf%9d%e8%ad%89%e4%ba%86%e5%97%8e%ef%bc%9f%e4%b8%8d%e8%a6%81%e5%86%8d%e4%bf%a1%e5%bb%a0%e5%95%86%e8%aa%aa%e4%bb%96%e5%80%91%e6%98%af-fda-approved-%e8%aa%8d/)

FDA ä¹‹å‰éƒ½æ˜¯çœä¸€éš»çœ¼é–‰ä¸€éš»çœ¼ï¼Œä¸éå¾è¥¿å…ƒ 2020 å¹´ 7 æœˆé–‹å§‹ï¼ŒFDA é–‹å§‹çµ¦ 7 å€‹éŠ·å”® NAC çš„ä¿å¥å“å…¬å¸ç™¼å‡ºè­¦å‘Šä¿¡ï¼Œåœ¨è­¦å‘Šä¿¡ä¸­æåˆ° NAC åœ¨è¥¿å…ƒ 1963 å¹´å·²ç¶“è¢«åˆ—ç‚ºäº†è—¥ç‰©ï¼Œæ ¹æ“šç¾åœ‹è¯é‚¦é£Ÿå“ã€è—¥å“å’ŒåŒ–å¦å“æ³•æ¡ˆçš„Section 201(ff)(3)(B)(i)ï¼Œä¸€å€‹å·²ç¶“è¢«åˆ—ç‚ºè—¥ç‰©çš„ç‰©è³ªç„¡æ³•è¢«ä½œç‚ºç‡Ÿé¤Šè£œå……åŠ‘ä½¿ç”¨ã€‚

æ‰€ä»¥åœ¨è¥¿å…ƒ 2021 å¹´ä¸ŠåŠå¹´ï¼Œç¾åœ‹ Amazon ä¸‹æ¶äº†æ‰€æœ‰å«æœ‰ NAC çš„ç”¢å“ã€‚

é€™ä¸‹å­çµ¦ Metrobiotech å…¬å¸æ‰¾åˆ°ä¸€å€‹è—‰å£ï¼Œä»–æƒ³ã€Œç¨ä½”ã€é€™å€‹å¸‚å ´ã€‚å¦‚æœæˆåŠŸçš„è©±ï¼Œå°‡æ˜¯ä¸€ç­†ä¸Šåƒå„„ç¾é‡‘çš„å¸‚å ´å•Šï¼

è€Œåœ¨è¥¿å…ƒ 2022 å¹´ 2 æœˆç™¼è¡¨æœ€æ–°ç ”ç©¶æˆæœé¡¯ç¤ºï¼Œç ”ç©¶åœ˜éšŠæ¡ç”¨äº†éš¨æ©Ÿå°ç…§é›™ç›²å¯¦é©—ï¼Œå°‡ 32 åè¶…é‡æˆ–è‚¥èƒ–çš„è€å¹´å—è©¦è€…ï¼ˆ55 ~ 80 æ­²ï¼‰åˆ†ç‚º 3 çµ„ 14 å¤©å…§ï¼Œ12 äººæ¯å¤©æœç”¨ 1 æ¬¡ 1000 mg çš„ MIB-626ï¼›12äººæ¯å¤©æœç”¨ 2 æ¬¡ï¼Œæ¯æ¬¡å„ 1000 mgï¼›å…¶é¤˜äººæœç”¨å®‰æ…°åŠ‘ã€‚æ‰€æœ‰å—è©¦è€…å‡ç„¡é‡å¤§å¥åº·å•é¡Œï¼Œä¹Ÿæœªæ›¾æœç”¨é NAD+ è£œå……åŠ‘ã€‚

çµæœç™¼ç¾ï¼Œè¡€æ¶²ä¸­ NAD å‰é©…ç‰©æ¿ƒåº¦å¤§å¹…ä¸Šå‡ï¼Œä¸‰çµ„å—è©¦è€…å°¿æ¶²ä¸­çš„ NMN æ¿ƒåº¦æ²’æœ‰é¡¯è‘—å·®ç•°ï¼Œé€™è¡¨æ˜å£æœ MIB-626 å¾Œè—¥ç‰©ä¸æœƒä»¥ NMN å½¢å¼é€šéå°¿æ¶²æ’å‡ºé«”å¤–ã€‚

é€²ä¸€æ­¥ç ”ç©¶ç™¼ç¾ï¼Œæœç”¨ MIB-626 çš„å—è©¦è€…ï¼Œå°¿æ¶²ä¸­ NAD+ å¾ªç’°ä»£è¬ç”¢ç‰©è¸é…°èƒºï¼ˆNAMï¼‰å’ŒN-ç”²åŸº-2-å¡å•¶é…®-5-ç¾§é…°èƒºï¼ˆN1-methyl-2-pyridone-5-carboxamideï¼Œ2-PYï¼‰å¹³å‡æ¿ƒåº¦é«˜æ–¼å°ç…§çµ„ï¼Œæš—ç¤ºä»–å€‘æœç”¨çš„ MIB-626 åœ¨é«”å…§è¢«è½‰åŒ–ç‚º NAD+ å¸æ”¶åˆ©ç”¨ã€‚

MIB-626å¯¦é©—çµæœ

å¦‚æœ FDA åŒæ„å…¶å…¬å¸è¦æ±‚æˆç«‹çš„è©±ï¼Œä»¥å¾Œä½ ä¹Ÿåªèƒ½è·Ÿä»–è²·äº†ã€‚

## **ç†±é‡é™åˆ¶æ¨¡æ“¬ç‰©æ˜¯è§£æ–¹**

ä¸éçœŸçš„æƒ³è¦å…¨èº«æ€§æŠ—è¡°è€ï¼Œå¿…é ˆå¾æ ¹æœ¬å•é¡Œä¸Šå»é™ä½ NAD+ çš„è®ŠåŒ–ï¼Œè€Œ**ç†±é‡é™åˆ¶æ³•** å°±æ˜¯é‚£å€‹æœ€é‡è¦çš„é—œéµï¼Œé‚£**ç†±é‡é™åˆ¶æ¨¡æ“¬ç‰©** ï¼ˆCalorie Restriction Mimeticsï¼ŒCRMï¼‰å°±æ˜¯æœªä¾†æœ€é‡è¦çš„è§£æ±ºæ˜ç‡ˆï¼

ç†±é‡é™åˆ¶æŠ—è€åŒ–

æœ‰é—œç†±é‡é™åˆ¶æ¨¡æ“¬ç‰©æ–‡ç« è«‹çœ‹é€™ä¸€ç¯‡ï¼š

ğŸ‘‡ğŸ‘‡ğŸ‘‡ğŸ‘‡ğŸ‘‡ğŸ‘‡ğŸ‘‡ğŸ‘‡

> [åä¸€é¡†å°±èƒ½æŠ—è¡°è€ï¼ç¾ä»£ç‰ˆçš„ã€Œé•·ç”Ÿä¸è€è—¥ã€å•ä¸–](https://agelocked.com/%e5%90%9e%e4%b8%80%e9%a1%86%e5%b0%b1%e8%83%bd%e6%8a%97%e8%a1%b0%e8%80%81%ef%bc%81%e7%8f%be%e4%bb%a3%e7%89%88%e7%9a%84%e3%80%8c%e9%95%b7%e7%94%9f%e4%b8%8d%e8%80%81%e8%97%a5%e3%80%8d%e5%95%8f%e4%b8%96/)

åƒè€ƒè³‡æ–™ï¼š  
01.çŸ¥ä¹/æ™‚å…‰æ´¾/[å‰æ²¿å¿«è®¯ï¼šâ€œä¸è€è¯â€NMNå’ŒNRçš„æœ¬è´¨ï¼Œå››å·å¤§å­¦å›¢é˜Ÿä¸ºä½ è®²è§£å…³äºNAD+çš„ä¸€åˆ‡](https://zhuanlan.zhihu.com/p/267696603)  
02.çŸ¥ä¹/æ™‚å…‰æ´¾/[æå˜‰è¯šçš„â€œä¸è€è¯â€æœ‰å“ªäº›åŠŸæ•ˆï¼Ÿå››å·å¤§å­¦æœ€æ–°æœ€å…¨è§£](https://zhuanlan.zhihu.com/p/274379409)  
03.çŸ¥ä¹/æ™‚å…‰æ´¾/[ä¸œäº¬å¤§å­¦å…¬å¸ƒâ€œä¸è€è¯â€NMNäººä½“ä¸´åºŠç»“æœï¼æ”¹å–„å¥åº·è€äººè‚Œè‚‰åŠ›é‡ï¼Œè€å¹´äººä¸å†æ€•æ‘”è·¤ï¼](https://zhuanlan.zhihu.com/p/391155628)  
04.çŸ¥ä¹/æ™‚å…‰æ´¾/[å¼¯é“è¶…è½¦ï¼ä¸­å›½é¦–ä¸ªâ€œä¸è€è¯â€NMNä¸´åºŠç»“æœå‡ºç‚‰ï¼Œä¸“ä¸ºæˆ‘å›½ä¸­å¹´äººè®¾è®¡ï¼å¯æå‡å¤šé¡¹å…³é”®ä½“å¾](https://zhuanlan.zhihu.com/p/389755320)  
05.çŸ¥ä¹/æ™‚å…‰æ´¾/[æŠ—è¡°è€ç ”ç©¶æ–°æ—¶ä»£ï¼å¯Œå•†å­¦è€…ä»¬æœ€çˆ±çš„â€œä¸è€è¯â€NMNå…¨çƒé¦–ä¸ªäººä½“ä¸´åºŠç»“æœå‡ºç‚‰ï¼Œæ”¹å–„ä»£è°¢è¡°è€ï¼Œç»†èŠ‚è®©äººå¿§æ„](https://zhuanlan.zhihu.com/p/367316140)  
06.çŸ¥ä¹/æ™‚å…‰æ´¾/[é‡ç£…ç»¼è¿° | åæµã€å¯Œå•†ä»¬éƒ½çˆ±åƒçš„â€œä¸è€è¯â€ï¼Œç©¶ç«Ÿä¸ºä½•æŠ—è¡°ï¼Ÿé¡¶çº§æœŸåˆŠå¸¦æ¥â€œä¿å§†çº§â€è®²è§£](https://zhuanlan.zhihu.com/p/376922137)  
07.çŸ¥ä¹/æ™‚å…‰æ´¾/[æå‡NAD+æ–¹å¼æ¯”è¾ƒï¼ŒçƒŸé…°èƒº/NAMå¯èƒ½æ˜¯ä¸€ä¸ªç³Ÿç³•çš„ç­–ç•¥](https://zhuanlan.zhihu.com/p/71955985)  
08.çŸ¥ä¹/æ™‚å…‰æ´¾/[â€œNMNæ•™çˆ¶â€è¾›å…‹è±è¦æ±‚FDAä¸‹æ¶æ‰€æœ‰NMNï¼Œå·²æ‚„ç„¶å¼€å±•è¶…çº§NAD+ä¸´åºŠ](https://zhuanlan.zhihu.com/p/453941483)  
09.çŸ¥ä¹/å­™åšå£«/[NAD+çš„å†…å¾ªç¯ â€“ è¿œæ¯”è¡¥å……å‰ä½“æ›´é‡è¦çš„è¿‡ç¨‹](https://zhuanlan.zhihu.com/p/82987058)  
10.çŸ¥ä¹/å­™åšå£«/[å…¨ç¾çš„NMNäº§å“è¦ä¸‹æ¶äº†ï¼Ÿå­¦æœ¯ç“œçš„åç»­](https://zhuanlan.zhihu.com/p/445216321)  
11.åº·å¥/æ¢å…ƒé½¡/[ç¾è»ç ”ç™¼ã€ŒæŠ—è€è—¥ä¸¸ã€ï¼Œå¯ç¶­æŒèº«é«”æ©Ÿèƒ½ã€æ”¾æ…¢é€€åŒ–é€Ÿåº¦ï¼Œé‚„èƒ½å¹«åŠ©å‚·å…µç—Šç™’å¾—æ›´å¿«](https://www.commonhealth.com.tw/article/84880)  
12.äºæ´²ç™Œç—‡ç ”ç©¶åŸºé‡‘æœƒè‚¡ä»½æœ‰é™å…¬å¸/[æœ€ç«æŠ—è¡°è€ã€Œç¥è‘¯ã€æˆ–ä¿ƒç™Œï¼Ÿè£œå……NAD+æœƒä¿ƒé€²è¡°è€ç´°èƒçš„åˆ†æ³Œè¡¨ç¾ï¼Œåˆºæ¿€ç™Œç´°èƒç”Ÿé•·  
](https://afcr.org/zh/2019/03/06/%E6%9C%80%E7%81%AB%E6%8A%97%E8%A1%B0%E8%80%81%E3%80%8C%E7%A5%9E%E8%91%AF%E3%80%8D%E6%88%96%E4%BF%83%E7%99%8C%EF%BC%9F%E8%A3%9C%E5%85%85nad%E6%9C%83%E4%BF%83%E9%80%B2%E8%A1%B0%E8%80%81%E7%B4%B0/)13.TIME/Alice Park/[NAD+æœƒæ˜¯äººé¡è¿”è€é‚„ç«¥çš„å¸Œæœ›å—ï¼Ÿ](https://www.thenewslens.com/feature/timefortune/65332)  
14.åŒ—äº¬æ–°æµªç¶²/[å¤šä½å“ˆä½›æ•™æˆåŠ›è–¦çš„ã€Œé•·ç”Ÿä¸è€è‘¯ã€NMNèƒ½åƒå—ï¼Ÿ](https://news.sina.com.tw/article/20200814/36040170.html)  
15\. Laurent Mouchiroud, Riekelt H Houtkooper, Norman Moullan, Elena Katsyuba, Dongryeol Ryu, Carles CantÃ³, Adrienne Mottis, Young-Suk Jo, Mohan Viswanathan, Kristina Schoonjans, Leonard Guarente, Johan Auwerx, 2013. [NAD(+)/Sirtuin Pathway Modulates Longevity through Activation of Mitochondrial UPR and FOXO Signaling.](https://pubmed.ncbi.nlm.nih.gov/23870130/) _Cell_ 154(2): 430-41.  
16\. Xiao-Hong Zhu, Ming Lu, Byeong-Yeul Lee, Kamil Ugurbil, Wei Chen, 2015. [In vivo NAD assay reveals the intracellular NAD contents and redox state in healthy human brain and their age dependences.](https://pubmed.ncbi.nlm.nih.gov/25730862/) _PNAS_ 112(9): 2876-81.  
17\. Jun Yoshino, Kathryn F. Mills, Myeong Jin Yoon, and Shin-ichiro Imai, 2011. [Nicotinamide mononucleotide, a key NAD+ intermediate, treats the pathophysiology of diet-and age-induced diabetes in mice.](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3204926/) _Cell Metab_. 14(4): 528-536.  
18\. Laurent Mouchiroud, Riekelt H Houtkooper, Johan Auwerx, 2013. [NADâº metabolism: a therapeutic target for age-related metabolic disease. ](https://pubmed.ncbi.nlm.nih.gov/23742622/)_Review Crit Rev Biochem Mol Biol._ 48(4):397-408.  
19\. Dietrich Conze, Charles Brenner, Claire L Kruger, 2019. [Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults. ](https://pubmed.ncbi.nlm.nih.gov/31278280/)_Sci Rep._ 9(1):9772.  
20\. Junichiro Irie, Emi Inagaki, Masataka Fujita, Hideaki Nakaya, Masanori Mitsuishi, Shintaro Yamaguchi, Kazuya Yamashita, Shuhei Shigaki, Takashi Ono, Hideo Yukioka, Hideyuki Okano, Yo-Ichi Nabeshima, Shin-Ichiro Imai, Masato Yasui, Kazuo Tsubota, Hiroshi Itoh, 2020. [Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men.](https://pubmed.ncbi.nlm.nih.gov/31685720/) _Endocr J._ 67(2):153-160.  
21\. Mihoko Yoshino, Jun Yoshino, Brandon D Kayser, Gary J Patti, Michael P Franczyk, Kathryn F Mills, Miriam Sindelar, Terri Pietka, Bruce W Patterson, Shin-Ichiro Imai, Samuel Klein, 2021. [Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women.](https://pubmed.ncbi.nlm.nih.gov/33888596/) _Science_. 372(6547):1224-1229.  
22\. Masaki Igarashi, Masaomi Miura, Yoshiko Nakagawa-Nagahama, Keisuke Yaku, Kosuke Kashiwabara, Mika Sawada, Rie Sekine, Yuichiro Fukamizu, Toshiya Sato, Takanobu Sakurai, Jiro Sato, Kenji Ino, Naoto Kubota, Takashi Nakagawa, Takashi Kadowaki, Toshimasa Yamauchi, 2021. [Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle motility in healthy old men.](https://assets.researchsquare.com/files/rs-455083/v1_covered.pdf7) _Nat. Portfolio._ DOI:10.21203/rs.3.rs-455083/v1  
23\. Bagen Liao, Yunlong Zhao, Dan Wang, Xiaowen Zhang, Xuanming Hao, Min Hu, 2021. [Nicotinamide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study.](https://pubmed.ncbi.nlm.nih.gov/34238308/) _J. Int. Soc. Sports Nutr._ 18(1):54.  
24\. Melanie R McReynolds, Karthikeyani Chellappa, Eric Chiles, Connor Jankowski, Yihui Shen, Li Chen, HÃ©lÃ¨ne C Descamps, Sarmistha Mukherjee, Yashaswini R Bhat, Siddharth R Lingala, Qingwei Chu, Paul Botolin, Faisal Hayat, Tomohito Doke, Katalin Susztak, Christoph A Thaiss, Wenyun Lu, Marie E Migaud, Xiaoyang Su, Joshua D Rabinowitz, Joseph A Baur, 2021. [NAD+ flux is maintained in aged mice despite lower tissue concentrations.](https://pubmed.ncbi.nlm.nih.gov/34559996/) _Cell Syst._ S2405-4712(21)00338-0.  
25\. Na Xie, Lu Zhang, Wei Gao, Canhua Huang, Peter Ernst Huber, Xiaobo Zhou, Changlong Li, Guobo Shen, Bingwen Zou, 2020. [NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential.](https://pubmed.ncbi.nlm.nih.gov/33028824/) _Signal Transduct Target Ther._ 5(1):227.  
26\. Ling Liu, Xiaoyang Su, William J Quinn, Sheng Hui, Kristin Krukenberg, David W Frederick, Philip Redpath, Le Zhan, Karthikeyani Chellappa, Eileen White, Marie Migaud, Timothy J Mitchison, Joseph A Baur, Joshua D Rabinowitz, 2018. [Quantitative Analysis of NAD Synthesis-Breakdown Fluxes.](https://pubmed.ncbi.nlm.nih.gov/29685734/) _Cell Metab._ 27(5):1067â€“1080.  
27\. Michael B. Schultz and David A. Sinclair, 2016. [Why NAD(+) Declines during Aging: Itâ€™s Destroyed.](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5088772/) _Cell Metab._ 23(6):965â€“966.  
28\. Anthony J Covarrubias, Rosalba Perrone, Alessia Grozio, Eric Verdin, 2021. [NAD+ metabolism and its roles in cellular processes during ageing.](https://pubmed.ncbi.nlm.nih.gov/33353981/) _Nat Rev Mol Cell Biol._ 22(2):119â€“141.  
25\. Julie A Mattison, Ricki J Colman, T Mark Beasley, David B Allison, Joseph W Kemnitz, George S Roth, Donald K Ingram, Richard Weindruch, Rafael de Cabo, Rozalyn M Anderson, 2017. [Caloric restriction improves health and survival of rhesus monkeys.](https://pubmed.ncbi.nlm.nih.gov/28094793/) _Nat Commun._ 8:14063.  
29\. Jie Song, Sen-Fang Ke, Can-Can Zhou, Sai-Long Zhang, Yun-Feng Guan, Tian-Ying Xu, Chun-Quan Sheng, Pei Wang, Chao-Yu Miao, 2014. [Nicotinamide phosphoribosyltransferase is required for the calorie restriction-mediated improvements in oxidative stress, mitochondrial biogenesis, and metabolic adaptation.](https://pubmed.ncbi.nlm.nih.gov/23946338/) _J Gerontol A Biol Sci Med Sci._ 69(1):44-57.  
30\. Angeliki Chalkiadaki, Leonard Guarente, 2012. [Sirtuins mediate mammalian metabolic responses to nutrient availability. ](https://pubmed.ncbi.nlm.nih.gov/22249520/)_Nat Rev Endocrinol._ 8(5):287-96.  
31.Stephen R Spindler, 2010. [Caloric restriction: from soup to nuts.](https://pubmed.ncbi.nlm.nih.gov/19853062/) _Ageing Res Rev._ 9(3):324â€“353.  
32\. David W Frederick, James G Davis, Antonio DÃ¡vila Jr, Beamon Agarwal, Shaday Michan, Michelle A Puchowicz, Eiko Nakamaru-Ogiso, Joseph A Baur, 2015. [Increasing NAD synthesis in muscle via nicotinamide phosphoribosyltransferase is not sufficient to promote oxidative metabolism.](https://pubmed.ncbi.nlm.nih.gov/25411251/) _J Biol Chem._ 290(3):1546â€“1558.  
33\. Xiaojing Wei, Ru Jia, Guan Wang, Shangyu Hong, Lin Song, Bo Sun, Ke Chen, Nan Wang, Qiqi Wang, Xiao Luo, Jianqun Yan, 2020. [Depot-specific regulation of NAD +/SIRTs metabolism identified in adipose tissue of mice in response to high-fat diet feeding or calorie restriction.](https://pubmed.ncbi.nlm.nih.gov/32278117/) _J Nutr Biochem._ 80:108377.  
34\. Yunlu Sheng, Fan Xia, Lei Chen, Yifan Lv, Shan Lv, Jing Yu, Juan Liu, Guoxian Ding, 2021. [Differential Responses of White Adipose Tissue and Brown Adipose Tissue to Calorie Restriction During Aging. ](https://pubmed.ncbi.nlm.nih.gov/32222773/)_J Gerontol A Biol Sci Med Sci._ 76(3):393-399.  
35\. Patricia Corrales, Yurena Vivas, Adriana Izquierdo-Lahuerta, Daniel Horrillo, Patricia Seoane-Collazo, Ismael Velasco, Lucia Torres, Yamila Lopez, Carmen MartÃ­nez, Miguel LÃ³pez, Manuel Ros, Maria Jesus Obregon, Gema Medina-Gomez, 2019. [Long-term caloric restriction ameliorates deleterious effects of aging on white and brown adipose tissue plasticity. ](https://pubmed.ncbi.nlm.nih.gov/30920127/)_Aging Cell._ 18(3):e12948.  
36\. Mitsukuni Yoshida, Akiko Satoh, Jonathan B Lin, Kathryn F Mills, Yo Sasaki, Nicholas Rensing, Michael Wong, Rajendra S Apte, Shin-Ichiro Imai, 2019. [Extracellular Vesicle-Contained eNAMPT Delays Aging and Extends Lifespan in Mice.](https://pubmed.ncbi.nlm.nih.gov/31204283/) _Cell Metab._ 30(2):329-342.e5.  
37\. Stephen J. Gardell, Meghan Hopf, Asima Khan, Mauro Dispagna, E. Hampton Sessions, Rebecca Falter, Nidhi Kapoor, Jeanne Brooks, Jeffrey Culver, Chris Petucci, Chen-Ting Ma, Steven E. Cohen, Jun Tanaka, Emmanuel S. Burgos, Jennifer S. Hirschi, Steven R. Smith, Eduard Sergienko & Anthony B. Pinkerton, 2019. [NAD+ with a small molecule that activates NAMPT.](https://www.nature.com/articles/s41467-019-11078-z) _Nature Communications_. 10, Article number: 3241.  
38\. Karol Pencina, Siva Lavu, Marcello Dos Santos, Yusnie Memish Beleva, Ming Cheng, David Livingston, Shalender Bhasin, 2022. [MIB-626, an Oral Formulation of a Microcrystalline Unique Polymorph of Î²-Nicotinamide Mononucleotide, Increases Circulating Nicotinamide Adenine Dinucleotide and its Metabolome in Middle-aged and Older Adults.](https://pubmed.ncbi.nlm.nih.gov/35182418/) _J Gerontol A Biol Sci Med Sci._ glac049.  
39\. Li Li Ji, and Dongwook Yeo, 2022. [Maintenance of NAD+ Homeostasis in Skeletal Muscle during Aging and Exercise.](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8869961/) _Cell._ doi: 10.3390/cells11040710.  
40\. Anthony J. Covarrubias, Rosalba Perrone, Alessia Grozio & Eric Verdin, 2020. [NAD+ metabolism and its roles in cellular processes during ageing.](https://www.nature.com/articles/s41580-020-00313-x) _Nature Reviews Molecular Cell Biology._ 22(2),119â€“141.  
41\. Mijin Kim, Jaehoon Seol, Toshiya Sato, Yuichiro Fukamizu, Takanobu Sakurai, Tomohiro Okura, 2022. [Effect of 12-Week Intake of Nicotinamide Mononucleotide on Sleep Quality, Fatigue, and Physical Performance in Older Japanese Adults: A Randomized, Double-Blind Placebo-Controlled Study.](https://pubmed.ncbi.nlm.nih.gov/35215405/) _Nutrients._ 14(4):755.

å–œæ­¡æˆ‘å¯«çš„å…§å®¹å—?  
è«‹é»é¸åŠ å…¥å¦‚æ–°ä¿å¥å“å°ˆå®¶ageLOCå¤å°ˆå€å‘Šè¨´æˆ‘ä½ çš„æ„Ÿæƒ³èˆ‡è©•è«– ğŸ‘‡ğŸ‘‡ğŸ‘‡ğŸ‘‡  

[ å¦‚æ–°ä¿å¥å“å°ˆå®¶ageLOCå¤æœƒå“¡å°ˆå€ ](https://lin.ee/jgugMvX)

æƒ³ç¬¬ä¸€æ‰‹æ¥æ”¶ç”¢å“å¿«è¨Šèˆ‡ç§‘å­¸æ–°çŸ¥å—ï¼Ÿ  
æœ‰æ­é…å¦‚æ–°ä¿å¥å“å•é¡Œæƒ³å•å—ï¼Ÿ  
è«‹é»é¸åŠ å…¥å¦‚æ–°ä¿å¥å“å°ˆå®¶ageLOCå¤å°ˆå€åšè«®è©¢ ğŸ‘‡ğŸ‘‡ğŸ‘‡ğŸ‘‡  

[ å¦‚æ–°ä¿å¥å“å°ˆå®¶ageLOCå¤æœƒå“¡å°ˆå€ ](https://lin.ee/jgugMvX)
